Latent View Analytics Ltd Share Price – NSE  /  BSE

IT - Software, Small Cap

Latent View Analytics will hold a meeting of the Board of Directors of the Company on 7 May 2024.

Powered by Capital Market - Live News

The key indices traded with strong gains in early afternoon trade. The Nifty marched above 22,350 mark. Pharma shares gained after declining in the two trading session. Trading could be volatile due to the March F&O series expiry today.

At 12:27 IST, the barometer index, the S&P BSE Sensex was surged 765.04 points or 1.05% to 73,758.08. The Nifty 50 index jumped 237.50 points or 1.07% to 22,361.15.

The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index rose 0.58% and the S&P BSE Small-Cap index added 0.69%.

The market breadth was strong. On the BSE, 2,204 shares rose and 1,454 shares fell. A total of 131 shares were unchanged.

Derivatives:

The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, shed 0.19% to 12.68. The Nifty 28 March 2024 futures were trading at 22,510.45, at a premium of 149.3 points as compared with the spot at 22,361.15.

The Nifty option chain for the 28 March 2024 expiry showed maximum Call OI of 257 lakh contracts at the 22,500 strike price. Maximum Put OI of 307.5 lakh contracts were seen at 22,300 strike price.

Buzzing Index:

The Nifty Pharma rose 1.01% to 18,957.05. The index shed 0.25% in the two trading sessions.

Biocon (up 3.39%), Divis Laboratories (up 2.15%), Ipca Laboratories (up 2.14%), Cipla (up 1.78%) and Zydus Lifesciences (up 1.78%), Dr Reddys Laboratories (up 1.75%), Sanofi India (up 1.29%), Sun Pharmaceuticals Industries (up 1.15%), Abbott India (up 1.04%) and Granules India (up 0.85%) advanced.

On the other hand, Mankind Pharma (down 2.17%), Alkem Laboratories (down 1.62%) and Natco Pharma (down 1.18%) edged lower.

Zydus Lifesciences rose 1.78% after the company said that US Food and Drug Administration (USFDA) conducted an inspection at the SEZ Onco Injectable manufacturing plant at Ahmedabad, Gujarat.

Biocon jumped 3.39% after the company announced that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide.

Stocks in Spotlight:

Latent View Analytics advanced 4.18% after the company announced the Board approval for acquisition of 70% of outstanding equity capital in Decision Point for a total consideration of $39.1 million.

Powered by Capital Market - Live News

The remaining 30% equity is to be acquired over the next 2 years with a pay-out based on agreed valuation principles.

Established in 2012, Decision Point is a leader in AI-led business transformation and revenue growth management (RGM) solutions with 300+ employees worldwide. The company brings deep experience in RGM, demand forecasting, pricing analytics, promotion analytics, retail segmentation, and marketing mix models with a focus on CPG brands.

Decision Point has over a decade of experience developing AI-powered solutions, including Beagle GPT, a conversational GenAI app for Microsoft Teams used by Fortune 500 consumer packaged goods (CPG) customers to drive data analytics usage within their firms. Decision Point had recorded a turnover and a net profit of Rs 86.99 crore and Rs 22.63 crore, respectively.

LatentView Analytics provides business transformation consulting and works with companies to develop and implement flexible and agile analytics roadmaps. The acquisition of Decision Point will bolster LatentView’s existing expertise in data engineering, data science, data visualization, as well as consulting and advisory services for analytics and GenAI readiness.

LatentView will make investments to accelerate the expansion of Decision Point solutions in the focus markets of North America and Europe.

Rajan Sethuraman, CEO, LatentView Analytics, said: “Decision Point’s strength in Revenue Growth Management solutions that help companies achieve sustainable and profitable growth with data, was the primary factor in this acquisition. Additionally, this deal will bring 300+ highly skilled employees into LatentView’s CPG practice and help us expand into the Latin America market.”

Rajan Venkatesan, CFO, LatentView Analytics, said: “With the acquisition of Decision Point, we are honoring our commitment of staying focused on our core verticals. This acquisition will be fully funded from our existing cash reserves. We expect the transaction to be EBIDTA accretive, driving enduring and strategic benefits for our clients.”

Latent View Analytics (LatentView) is a global data analytics company. The company provides a 360-degree view of the digital consumer, enabling companies to predict new revenue streams, anticipate product trends and popularity, improve customer retention rates, and optimize investment decisions.

The company’s consolidated net profit declined 11.34% to Rs 46.52 crore despite a 13.99% rise in revenue to Rs 165.69 crore in Q3 FY24 over Q3 FY23.

Powered by Capital Market - Live News

Net profit of Latent View Analytics declined 11.34% to Rs 46.52 crore in the quarter ended December 2023 as against Rs 52.47 crore during the previous quarter ended December 2022. Sales rose 13.99% to Rs 165.69 crore in the quarter ended December 2023 as against Rs 145.35 crore during the previous quarter ended December 2022.

Powered by Capital Market - Live News